Antiviral efficacy of adefovir dipivoxil in the treatment of chronic hepatitis B subjects from Indian subcontinent.
Loading...
Date
2014-01
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Adefovir is one of the therapeutic options for the treatment of chronic hepatitis B. A total of 30 adefovir-experienced
subjects with the median treatment duration of 12 (interquartile range (IQR) 6-18) months were studied. Virological
response was measured by hepatitis B virus deoxyribonucleic acid (HBV DNA) levels. HBV reverse transcriptase (rt)
domains were sequenced for the identifi cation of resistance mutations. Among the 30 subjects, two (7%) showed
virological response and 19 (63%) were non-responders. The virological response for the remaining nine (30%) subjects
was not determined. On sequence analysis, two subjects were identifi ed with rtI169L and rtA181V mutation after
9 months and 18 months of adefovir treatment, respectively. Though the frequencies of adefovir resistance mutations are
low, a large majority of subjects showed non-response. Therefore, adefovir in the management of HBV should be used
judiciously.
Description
Keywords
Adefovir, chronic hepatitis B, drug resistance, hepatitis B virus
Citation
Ismail A M, Ramachandran J, Kannangai R, Abraham P. Antiviral efficacy of adefovir dipivoxil in the treatment of chronic hepatitis B subjects from Indian subcontinent. Indian Journal of Medical Microbiology. 2014 Jan- Mar ; 32 (1): 60-63.